Cynata Therapeutics Kicks Off Patient Enrollment

September 14, 2020

Cynata Therapeutics Kicks Off Patient Enrollment

Biotech company Cynata Therapeutics has begun enrolling patients in their mesenchymal COVID-19 (MEND) trial. The study will explore the efficacy of mesenchymal stem cells in adults diagnosed with severe cases of the virus. “MSCs represent a very promising therapeutic approach to a range of important diseases,” commented company CEO Ross MacDonald. Yourway can transport, store, and distribute even the most challenging drug products, making us the ideal logistics partner provider for all clinical trial needs.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?